Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling.

@article{Landersdorfer2018CombatingCA,
  title={Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling.},
  author={Cornelia B. Landersdorfer and Rajbharan Yadav and Kate E Rogers and Tae Hwan Kim and Beom Soo Shin and John D Boyce and Roger L. Nation and Jurgen B. Bulitta},
  journal={Antimicrobial agents and chemotherapy},
  year={2018},
  volume={62 4}
}
We aimed to prospectively validate an optimized combination dosage regimen against a clinical carbapenem-resistant Acinetobacter baumannii (CRAB) isolate (imipenem MIC, 32 mg/liter; tobramycin MIC, 2 mg/liter). Imipenem at constant concentrations (7.6, 13.4, and 23.3 mg/liter, reflecting a range of clearances) was simulated in a 7-day hollow-fiber infection… CONTINUE READING